Bayesian phase I/II adaptively randomized oncology trials with combined drugs

DOI10.1214/10-AOAS433zbMath1232.62155arXiv1108.1614WikidataQ41545724 ScholiaQ41545724MaRDI QIDQ641145

Ying Yuan, Guosheng Yin

Publication date: 21 October 2011

Published in: The Annals of Applied Statistics (Search for Journal in Brave)

Full work available at URL: https://arxiv.org/abs/1108.1614

zbMATH Keywords

drug combinationadaptive randomizationdose finding

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Related Items (3)

A Bayesian Phase I/II Trial Design for Immunotherapy ⋮ A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes ⋮ A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology

Cites Work

• Unnamed Item
• Unnamed Item
• Unnamed Item
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Dose-Finding Designs for HIV Studies
• Dose-Finding with Two Agents in Phase I Oncology Trials
• Statistical Inference Procedures for Bivariate Archimedean Copulas
• Design and Analysis of Phase I Clinical Trials
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Designs for Single- or Multiple-Agent Phase I Trials
• A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence
• Adaptive Rejection Metropolis Sampling within Gibbs Sampling
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• A Parallel Phase I/II Clinical Trial Design for Combination Therapies
• Two‐Dimensional Dose Finding in Discrete Dose Space

This page was built for publication: Bayesian phase I/II adaptively randomized oncology trials with combined drugs